KRW 18200.0
(0.94%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -6.7 Billion KRW | 51.94% |
2022 | -13.95 Billion KRW | -308.22% |
2021 | -3.41 Billion KRW | 85.2% |
2020 | -23.1 Billion KRW | -330.35% |
2019 | -5.36 Billion KRW | 55.15% |
2018 | -11.96 Billion KRW | -166.52% |
2017 | -4.49 Billion KRW | 83.54% |
2016 | -27.28 Billion KRW | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -1.87 Billion KRW | -9.89% |
2024 Q2 | -3.45 Billion KRW | -84.49% |
2023 FY | -6.7 Billion KRW | 51.94% |
2023 Q2 | -2.34 Billion KRW | -142.26% |
2023 Q3 | -1.69 Billion KRW | 27.69% |
2023 Q4 | -1.7 Billion KRW | -0.58% |
2023 Q1 | -967.2 Million KRW | 81.41% |
2022 Q2 | -2.14 Billion KRW | 23.72% |
2022 FY | -13.95 Billion KRW | -308.22% |
2022 Q4 | -5.2 Billion KRW | -36.95% |
2022 Q3 | -3.79 Billion KRW | -77.08% |
2022 Q1 | -2.81 Billion KRW | -72.11% |
2021 Q3 | -1.96 Billion KRW | 0.0% |
2021 Q4 | -1.63 Billion KRW | 16.99% |
2021 FY | -3.41 Billion KRW | 85.2% |
2020 FY | -23.1 Billion KRW | -330.35% |
2019 FY | -5.36 Billion KRW | 55.15% |
2018 FY | -11.96 Billion KRW | -166.52% |
2017 FY | -4.49 Billion KRW | 83.54% |
2016 FY | -27.28 Billion KRW | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 65.467% |
CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | 203.928% |
Celltrion Pharm, Inc. | 21.26 Billion KRW | 131.549% |
Huons Global Co., Ltd. | 38.38 Billion KRW | 117.479% |
DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 114.221% |
Enzychem Lifesciences Corporation | -9.32 Billion KRW | 28.065% |
Humedix Co., Ltd. | 24.82 Billion KRW | 127.03% |
Boditech Med Inc. | 25.94 Billion KRW | 125.857% |
EuBiologics Co., Ltd. | -13.87 Billion KRW | 51.661% |
Huons Co., Ltd. | 50.47 Billion KRW | 113.292% |
BNC Korea Co., Ltd. | 25.68 Billion KRW | 126.119% |
AptaBio Therapeutics Inc. | -12.06 Billion KRW | 44.378% |